Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

UPB

Upstream Bio Inc.

Oct 23 • 10:09AM ET

25.09

Dollar change +0.04
Percentage change 0.16	%

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-	Insider Own	59.40%	Shs Outstand	51.34M	Perf Week	6.18%
Market Cap	1.29B	Forward P/E	-	EPS next Y	-	Insider Trans	10.21%	Shs Float	20.85M	Perf Month	-
Income	-	PEG	-	EPS next Q	-	Inst Own	8.35%	Short Float	-	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf Year	-
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	20.74 - 27.68	Perf YTD	14.05%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-9.36%	Beta	-
Dividend TTM	-	Quick Ratio	-	Sales past 5Y	96.37%	Gross Margin	-	52W Low	20.97%	ATR (14)	2.22
Dividend Ex-Date	-	Current Ratio	-	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	-	Volatility	10.01% -
Employees	35	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	0.10	Prev Close	25.05
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	885.59K	Price	25.09
SMA20	3.81%	SMA50	3.81%	SMA200	3.81%	Trades		Volume	12,489	Change	0.16%

Oct-17-24 07:02PM	Orbimed Advisors LLC Acquires New Stake in Upstream Bio Inc (GuruFocus.com) +9.66%
Oct-15-24 04:15PM	Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks) +6.27%
Oct-10-24 07:35PM	Upstream Bio Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chimovits Erez	Director	Oct 15 '24	Buy	17.00	825,000	14,025,000	4,554,873	Oct 17 04:19 PM
ORBIMED ADVISORS LLC	Director	Oct 15 '24	Buy	17.00	825,000	14,025,000	4,554,873	Oct 17 04:17 PM
AI Upstream LLC	10% Owner	Oct 15 '24	Buy	17.00	1,175,000	19,975,000	1,175,000	Oct 17 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

UPB

Upstream Bio Inc.

Upgrade your FINVIZ experience